---
kind: "section"
citation: "42 U.S.C. § 280n"
title: "42"
title_heading: "The Public Health and Welfare"
number: "280n"
heading: "National Parkinson’s Project"
release: "119-102"
url: "https://uscodex.org/usc/42/280n"
units:
  - "Chapter 6A — Public Health Service"
  - "Subchapter II — General Powers and Duties"
  - "Part W — Parkinson’s and Related Disorders"
---

# §280n. National Parkinson’s Project

- (a) **Definition of Parkinson’s—** In this section, the term “Parkinson’s” means—
  - (1) [Parkinson](#a)’s disease; and
  - (2) all other neurodegenerative Parkinsonisms, including multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, and [Parkinson](#a)’s-related dementia.
- (b) **Establishment—** The [Secretary](/usc/42/201.md?p=c) shall carry out a national [project](/usc/42/11360.md?p=20), to be known as the National [Parkinson](#a)’s [Project](/usc/42/11360.md?p=20) (referred to in this section as the “[Project](/usc/42/11360.md?p=20)”), to prevent, diagnose, treat, and cure [Parkinson](#a)’s.
- (c) **Activities carried out through Project—** In carrying out the [Project](/usc/42/11360.md?p=20), the [Secretary](/usc/42/201.md?p=c) shall—
  - (1) create, maintain, and periodically update an integrated national plan to prevent, diagnose, treat, and cure [Parkinson](#a)’s, ameliorate symptoms, and slow or stop progression;
  - (2) carry out the annual assessment under [subsection (d)](#d);
  - (3) provide information, including—
    - (A) an estimate of the level of current Federal investment in preventing, diagnosing, treating, and curing [Parkinson](#a)’s, ameliorating symptoms, and slowing or stopping progression; and
    - (B) if applicable, an estimate of the investment necessary to prevent, diagnose, treat, and cure [Parkinson](#a)’s, ameliorate symptoms, and slow or stop progression;
  - (4) coordinate research and [services](/usc/42/201.md?p=a) across all [Federal agencies](/usc/42/300j–6.md?p=d-2) related to [Parkinson](#a)’s;
  - (5) encourage the development of safe and effective [treatments](/usc/42/11851.md?p=11), strategies, and other approaches to prevent, diagnose, treat, and cure [Parkinson](#a)’s, ameliorate symptoms, and slow or stop progression;
  - (6) improve the—
    - (A) early diagnosis of [Parkinson](#a)’s; and
    - (B) coordination of the care and [treatment](/usc/42/11851.md?p=11) of individuals with [Parkinson](#a)’s;
  - (7) review the impact of [Parkinson](#a)’s on the physical, mental, and social health of individuals living with [Parkinson](#a)’s and their caregivers and [families](/usc/42/12704.md?p=11);
  - (8) coordinate with international bodies, to the extent possible, to integrate and inform the mission to prevent, diagnose, treat, and cure [Parkinson](#a)’s, ameliorate symptoms, and slow or stop progression globally; and
  - (9) to the extent practicable, collaborate with other entities to prevent duplication of existing research activities for related disorders.
- (d) **Annual assessment—** Not later than 24 months after July 2, 2024, and annually thereafter, the [Secretary](/usc/42/201.md?p=c) shall carry out an assessment of the Nation’s progress in preparing for, and responding to, the escalating burden of [Parkinson](#a)’s, including—
  - (1) recommendations for priority actions based on the assessment;
  - (2) a description of any steps that are planned or have already been taken to implement such recommendations, including whether such recommendations can be implemented under existing law; and
  - (3) such other items as the [Secretary](/usc/42/201.md?p=c) determines appropriate.
- (e) **Advisory Council—**
  - (1) **In general—** The [Secretary](/usc/42/201.md?p=c) shall establish and maintain an [Advisory Council](/usc/42/274l–1.md?p=1) on [Parkinson](#a)’s Research, Care, and [Services](/usc/42/201.md?p=a) (referred to in this section as the “[Advisory Council](/usc/42/274l–1.md?p=1)”) to advise the [Secretary](/usc/42/201.md?p=c) on [Parkinson](#a)’s-related issues.
  - (2) **Membership—**
    - (A) **Federal members—** The [Advisory Council](/usc/42/274l–1.md?p=1) shall be comprised of experts, to be appointed by the [Secretary](/usc/42/201.md?p=c), who collectively are from various backgrounds and perspectives, including at least one member from each of—
      - (i) the Centers for Disease Control and Prevention;
      - (ii) the Administration on Community Living;
      - (iii) the Centers for Medicare & Medicaid [Services](/usc/42/201.md?p=a);
      - (iv) the National Institutes of Health;
      - (v) the Agency for Healthcare Research and Quality;
      - (vi) the Department of Veterans Affairs;
      - (vii) the Food and [Drug](/usc/42/282.md?p=j-1-A-vii) Administration;
      - (viii) the National Science [Foundation](/usc/42/17351.md?p=3);
      - (ix) the Department of Defense;
      - (x) the Environmental Protection Agency;
      - (xi) the [Office](/usc/42/3058f.md?p=1) of [Minority](/usc/42/299a–1.md?p=d-2) Health;
      - (xii) the [Indian](/usc/42/6862.md?p=6) Health [Service](/usc/42/201.md?p=a);
      - (xiii) the [Office](/usc/42/3058f.md?p=1) of the [Surgeon General](/usc/42/201.md?p=b) of the Public Health [Service](/usc/42/201.md?p=a); and
      - (xiv) other relevant Federal departments and agencies as determined by the [Secretary](/usc/42/201.md?p=c).
    - (B) **Non-federal members—** In addition to the members listed in [subparagraph (A)](#e-2-A), the [Advisory Council](/usc/42/274l–1.md?p=1) shall include 10 expert members, to be appointed by the [Secretary](/usc/42/201.md?p=c), who shall include [representatives](/usc/42/3058f.md?p=5) of [minority](/usc/42/299a–1.md?p=d-2) communities, communities disproportionately affected by [Parkinson](#a)’s, and communities underrepresented in [Parkinson](#a)’s research, who shall each be from outside the Federal Government, and who shall include—
      - (i) 2 [Parkinson](#a)’s patient advocates, at least 1 of whom is living with young-onset [Parkinson](#a)’s;
      - (ii) 1 [Parkinson](#a)’s [family](/usc/42/290ff–4.md?p=d-2) caregiver;
      - (iii) 1 [health care provider](/usc/42/300jj.md?p=3);
      - (iv) 2 biomedical researchers with [Parkinson](#a)’s-related expertise in basic, translational, clinical, or [drug](/usc/42/282.md?p=j-1-A-vii) development science;
      - (v) 1 movement disorder specialist who treats [Parkinson](#a)’s patients;
      - (vi) 1 dementia specialist who treats [Parkinson](#a)’s patients; and
      - (vii) 2 [representatives](/usc/42/3058f.md?p=5) from nonprofit organizations that have demonstrated experience in [Parkinson](#a)’s-related research or [Parkinson](#a)’s-related patient care and other [services](/usc/42/201.md?p=a).
    - (C) **Representation—** The [Secretary](/usc/42/201.md?p=c) shall ensure that the members of the [Advisory Council](/usc/42/274l–1.md?p=1) are collectively [representative](/usc/42/3058f.md?p=5) of agencies, professions, individuals, and entities concerned with, or affected by, activities under this section.
  - (3) **Meetings—**
    - (A) **Frequency—** The [Advisory Council](/usc/42/274l–1.md?p=1) shall meet—
      - (i) at least once each quarter during the 2-year period beginning on the date on which the [Advisory Council](/usc/42/274l–1.md?p=1) is established; and
      - (ii) at the [Secretary](/usc/42/201.md?p=c)’s discretion after such period.
    - (B) **Annual research meeting—** Not later than 24 months after July 2, 2024, and every year thereafter, the [Advisory Council](/usc/42/274l–1.md?p=1) shall convene a meeting of Federal and non-Federal organizations to discuss [Parkinson](#a)’s research.
    - (C) **Open meetings—** The meetings under subparagraphs [(A)](#e-3-A) and [(B)](#e-3-B) shall be open to the public.
  - (4) **Annual report—** Not later than 18 months after July 2, 2024, and every year thereafter, the [Advisory Council](/usc/42/274l–1.md?p=1) shall provide to the [Secretary](/usc/42/201.md?p=c) and Congress a report containing—
    - (A) a list of all federally-funded efforts in [Parkinson](#a)’s research, prevention, diagnosis, [treatment](/usc/42/11851.md?p=11), clinical care, and institutional-, home-, and community-based [programs](/usc/42/274l–1.md?p=4) and the outcomes of such efforts;
    - (B) recommendations for priority actions to expand, eliminate, coordinate, refocus, streamline, or condense Federal [programs](/usc/42/274l–1.md?p=4) based on each [program](/usc/42/274l–1.md?p=4)’s performance, mission, scope, and purpose;
    - (C) recommendations to—
      - (i) reduce the financial impact of [Parkinson](#a)’s on [families](/usc/42/12704.md?p=11) living with [Parkinson](#a)’s;
      - (ii) improve health outcomes for, and the quality of life of, individuals living with [Parkinson](#a)’s;
      - (iii) prevent [Parkinson](#a)’s, ameliorate symptoms, and slow or stop progression;
      - (iv) improve the quality of care provided to [beneficiaries](/usc/42/300gg–91.md?p=d-2) with [Parkinson](#a)’s who receive coverage through a federally-funded health care [program](/usc/42/274l–1.md?p=4), such as the Medicare [program](/usc/42/274l–1.md?p=4) under title XVIII of the Social Security Act [[42 U.S.C. 1395](/usc/42/1395.md) et seq.] or the Medicaid [program](/usc/42/274l–1.md?p=4) under title XIX of such Act [[42 U.S.C. 1396](/usc/42/1396.md) et seq.];
      - (v) research the association between environmental triggers and [Parkinson](#a)’s to help reduce exposure to potential triggers; and
      - (vi) research and better understand the underlying factors contributing to [Parkinson](#a)’s;
    - (D) priority actions to improve all federally-funded efforts in [Parkinson](#a)’s research, prevention, diagnosis, [treatment](/usc/42/11851.md?p=11), clinical care, and institutional-, home-, and community-based [programs](/usc/42/274l–1.md?p=4);
    - (E) an evaluation of the implementation, including outcomes, of the national plan under [subsection (c)(1)](#c-1); and
    - (F) implementation steps to address the recommendations and priority actions under subparagraphs [(B)](#e-4-B), [(C)](#e-4-C), and [(D)](#e-4-D), based in part on the evaluation under [subparagraph (E)](#e-4-E).
  - (5) **Termination—** The [Advisory Council](/usc/42/274l–1.md?p=1) shall terminate at the end of calendar year 2035.
- (f) **Information sharing—** Each Federal department and agency that has information relating to [Parkinson](#a)’s shall share such information with the [Secretary](/usc/42/201.md?p=c) consistent with the statutory obligations of such department or agency regarding disclosure of information, as necessary to enable the [Secretary](/usc/42/201.md?p=c) to complete a report under [subsection (e)(4)](#e-4).
- (g) **Sunset—** The section shall cease to be effective at the end of calendar year 2035.

## Source credit

(July 1, 1944, ch. 373, title III, § 399OO, as added Pub. L. 118–66, § 2, July 2, 2024, 138 Stat. 1443.)

## Notes

### Editorial Notes

### References in Text

The Social Security Act, referred to in subsec. (e)(4)(C)(iv), is act Aug. 14, 1935, ch. 531, 49 Stat. 620. Titles XVIII and XIX of the Act are classified generally to subchapters XVIII (§ 1395 et seq.) and XIX (§ 1396 et seq.), respectively, of chapter 7 of this title. For complete classification of this Act to the Code, see section 1305 of this title and Tables.